Evidence map›Paper›PMID 32639209›Full record

ArticleAIDS patient care and STDs2020

HIV Pre-Exposure Prophylaxis for Conception Among HIV Serodiscordant Couples in the United States: A Cohort Study.

Ashley A Leech, Dea Biancarelli, Erika Aaron, Emily S Miller, Jenell S Coleman, Peter L Anderson, Hervette Nkwihoreze, Brianne Condron, Meg Sullivan

Open access · greenAbstract read
In one paragraph

Article in AIDS patient care and STDs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Ashley A LeechDepartment of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Dea BiancarelliDepartment of Health Law, Policy and Management, Boston University School of Public Health, Boston, Massachusetts, USA.
Erika AaronDrexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Emily S MillerDivision of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois, USA.
Jenell S ColemanDepartment of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Peter L AndersonSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Hervette NkwihorezeDrexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Brianne CondronDivision of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois, USA.
Meg SullivanDepartment of Medicine, Center for Infectious Diseases, Boston Medical Center, Boston, Massachusetts, USA.
Drexel University · USNorthwestern University · USBoston Medical Center · USBoston University · USJohns Hopkins University · USUniversity of Colorado Anschutz Medical Campus · USVanderbilt Health · US

Funding

The effect of Depo-Provera on HIV susceptibility, immune activation, and PrEP PKR01AI110371 · NIAID · JOHNS HOPKINS UNIVERSITY · PI COLEMAN, JENELL S, HENDRIX, CRAIG WALTER · 2013 to 2017
$2.2M
NIAID NIH HHS R01 AI110371
6 · The paper itself

Abstract

Practice guidelines on pre-exposure prophylaxis (PrEP) for HIV serodiscordant couples recommend PrEP when the viral load of the partner living with HIV is either detectable or unknown. However, adherence to combination antiretroviral therapy is inconsistent, and research has found that individuals vulnerable to HIV place value on additional protective barriers. We conducted a prospective cohort study to assess the feasibility, perceptions, and adherence associated with periconceptional PrEP use among females without HIV and their male partners living with HIV across four academic medical centers in the United States. We performed descriptive statistics, McNemar's test of marginal homogeneity to assess discordance in female/male survey responses, and Spearman's correlation to determine associations between dried blood spot levels and female self-reported adherence to PrEP. We enrolled 25 women without HIV and 24 men living with HIV (one male partner did not consent to the study). Women took PrEP for a median of 10.9 months (interquartile range 3.8-12.0) and were generally adherent. In total, 87% of women (20/23) had a dried blood spot with >700 fmol/punch or ≥4 doses/week, 4% (1/23) at 350-699 fmol/punch or 2-3 doses/week, and 9% (2/23) at <350 fmol/punch or <2 doses/week (correlation between drug levels and adherence is based on prior data). Dried blood spot levels closely aligned with self-reported adherence (Spearman's rho = 0.64,

Indexed as

Anti-HIV AgentsChildCohort StudiesFemaleHIV InfectionsHIV SeropositivityHumansInfant, NewbornMalePre-Exposure ProphylaxisPregnancyProspective StudiesSexual PartnersSperm MotilityUnited StatesAnti-HIV AgentsconceptionHIVPrEPserodifferentserodiscordant

Identifiers

PMID32639209
PMCPMC7370981
OpenAlexW3042133875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.